Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 14 Jan 2026
This rheumatology month in review emphasizes new data from the ACR Convergence.
Read Full NewsTelemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.
A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.
A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.
1.
Study: Pre-operative THP leads to pCR in 64% of early-stage HER2+ ER- breast cancer patients
2.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
3.
3D virtual staining technology enables non-invasive observation of cancer tissue
4.
Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy
5.
Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows
1.
Exploring the Unknown: Unveiling the Mysteries of GIST Tumors
2.
Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life
3.
What Is A High MCV Level? Causes, Symptoms, And Treatment Options
4.
Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion
5.
How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge